Biogen Up 16% with Alzheimer’s Drug
The elusive Alzheimer’s disease may have a new sheriff in town with Biogen’s latest treatment BAN2401. Originally, BAN2401 failed in it’s preliminary round of testing. However, the company rebooted with a higher dosage and the tests came back with positive results on the effect of cognition and the accumulation of toxic plaques in the brain. In the second round of testing, patients who took a higher dose saw significant cognitive benefits compared with those in the control group. This has made shares of the biotech firm soar more than 16% in the last 24 hours.
